Rekvina Laboratories Ltd

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition by Surbhit Mukesh Shah and others.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to a substantial acquisition of shares by Dhruvalkumar Patel.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd clarifies that it is not aware of any undisclosed price-sensitive information or material event that may have a bearing on the price movement of its securities.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has announced its Q1 FY2026-27 financial results, with revenue from operations at Rs. 6 lacs, total income at Rs. 6.85 lacs, and a net loss of Rs. 12.05 lacs. The company has also appointed Mr. Surbhit Shah as the Chairman of the Board of Directors.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has announced its standalone unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 6 lacs, total income at Rs. 6.85 lacs, and a net loss of Rs. 12.05 lacs. The company has also appointed Mr. Surbhit Shah as the Chairman of the Board of Directors.

Rekvina Laboratories Ltd

The BSE has sought clarification from Rekvina Laboratories Ltd regarding significant price movement to ensure investors have relevant information.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has approved the allotment of 50,87,750 equity shares to promoters and non-promoters on a preferential basis, with Radiant Parenterals Limited becoming a wholly-owned subsidiary post-acquisition.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has scheduled a board meeting on 13th August, 2026 to consider and approve unaudited financial results for the quarter ended 30th June, 2026.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has received a post-offer advertisement for the acquisition of up to 28,90,100 equity shares by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel, representing 26% of the expanded share capital. The offer was made pursuant to the Securities and Exchange Board of India (Substantial Acquisitions of Shares and Takeovers) Regulations, 2011.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd has announced the results of its open offer, where the acquirers have acquired 28,90,100 equity shares representing 26% of the expanded share capital. The offer was made at Rs. 10 per share, and the acquirers have purchased 14,41,863 equity shares. The post-offer shareholding of the acquirers and promoters is 77.33% of the expanded share capital.

Rekvina Laboratories Ltd

Rekvina Laboratories Ltd announced receiving a Letter of Offer for an open offer to acquire up to 26% (2,890,100 shares) of its expanded share capital from public shareholders. The offer is made by Surbhit Mukesh Shah (a director), Amit Mukesh Shah, and Dhruvalkumar Patel at ₹10 per share. This open offer is in compliance with SEBI (SAST) Regulations, providing an exit opportunity for public shareholders and potentially leading to a consolidation of ownership or change in control.

Rekvina Laboratories Ltd

Vivro Financial Services Pvt Ltd has submitted a Letter of Offer for an Open Offer to the public shareholders of Rekvina Laboratories Ltd. Acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel propose to acquire up to 2,890,100 equity shares, representing 26% of the company's expanded share capital. The offer price is ₹10 per equity share, payable in cash. This offer is made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and provides an exit opportunity for public shareholders.